| Trading Avanir Pharmaceuticals' Impending Catalyst Event Tony Pelz submits:While the markets are crashing, it’s a good time to add to medium term catalyst trades. One name I am looking at is Avanir Pharmaceuticals (ticker: AVNR). The company’s lead Phase III candidate, Zenvia, is a drug targeting Pseudobulbar Affect (PBA) and according to the company, targets an underserved market of up to 2 million patients where there is currently no approved therapies (i.e. “no competition”). In 2006, the FDA issued the company an Approvable Letter, and following discussions with the FDA, AVNR agreed to conduct a confirmatory Phase III trail under an SPA for Zenvia. In August 2009, the company finally reported solid top-line data to address these FDA concerns. AVNR recently stated that they expect an FDA decision on Zenvia by October 30, 2010. Complete Story » seekingalpha.com |
FDA Details JNJ's Quality Issues New details emerged about quality-control issues at a Johnson & Johnson plant in Lancaster, Pa., the third to be cited by regulators in recent months. online.wsj.com |
Medivation, Inc. Q2 2010 Earnings Call Transcript Medivation, Inc. (MDVN)Q2 2010 Earnings Call TranscriptAugust 09, 2010 04:30 amComplete Story » seekingalpha.com |
Dialysis for the Busy Patient For most, kidney dialysis means sitting in a hospital hooked up to a machine for hours, three days a week. Although doing dialysis at home offers advantages, few patients have chosen to go this route. online.wsj.com |
Diet/Activity Lower Cancer Risk - Video Latest Research: Even Late in Life, Activity and Plant-Based Diet Lower Cancer Risk feedproxy.google.com |